Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.20M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 2.69M

Average 1.44M

CATX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Perspective Therapeutics, Inc.AMEX: CATX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $2.55M rose 21.7% year over year, behind the +38.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at +88.2% a year.

Context

  • Stock-based compensation amounted to 1014.3% of revenue in FY2025, up 643.8 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +21.7% toward the trailing-twelve-month pace of +38.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.55M+10.6% QoQ
Last fiscal yearDec 2025
$8.97M+66.4% YoY
LTMMar 2026
$9.42M+38.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.7%——
1 year+66.4%——
3-year CAGR+88.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
8.97M USD
Year-over-year change
+66.4%
4-year CAGR
+69.5%

Stock-Based Compensation vs competitors

How CATX compares with its peers on the latest reported figures

  • CATX's LTM Mar 2026 stock-based compensation of $9.42M is the 4th largest of the 5 companies compared; the peer median is $16.15M.
  • Its year-over-year change of +38.0% is the 3rd highest of 5, against a peer median of +27.5%.
  • Stock-based compensation amounts to 1524.4% of revenue for CATX, versus a peer median of 19.9%.
CATX Competitors Peer median
Stock-Based Compensation for CATX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$118.47M -23.8%—17.6%
DCTHDelcath Systems, Inc.LTM Mar 2026$22.32M +63.1%+45.0%24.7%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$9.98M +67.1%+191.7%22.2%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$9.42M +38.0%+88.2%1524.4%
SRTSSensus Healthcare, Inc.LTM Mar 2026$286K -8.0%+16.4%1.3%
Peer median (excluding CATX) $16.15M+27.5%+45.0%19.9%

Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.27M)(14.67M)(46.51M)(79.28M)(103.12M)
Depreciation & Amortization248K344K946K2.31M3.25M
Deferred Income Tax0(1.68M)(2.65M)(2.1M)(793K)
Stock-Based Compensation1.09M1.34M3.74M5.39M8.97M
Change in Working Capital(1.85M)338K2.3M31.81M1.68M
Accounts Receivables405K490K(426K)1.05M(32K)
Inventory(2.67M)(152K)359K11K0
Accounts Payables236K01.58M1.89M147K
Other Working Capital182K(28K)779K29.74M1.57M
Other Non-Cash Items77K472K5.27M55.39M7.53M
Operating Cash Flow(7.71M)(12.17M)(36.91M)(18.29M)(82.48M)
Capital Expenditures(266K)(302K)(1.07M)(54.41M)(12.75M)
Acquisitions (Net)002.7M00
Purchases of Investments000(243.51M)(119.84M)
Sales of Investments0022.76M0173.95M
Other Investing Activities(18K)(57.38M)(18K)78.99M(135K)
Investing Cash Flow(284K)(57.68M)24.37M(218.93M)41.23M
Debt Repayment——(68K)(48K)(52K)
Common Stock Issued56K0364K275.81M10.36M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities056K489K289.39M0
Financing Cash Flow56K56K785K289.39M10.31M
Effect of Forex Changes061.86M000
Net Change in Cash(7.94M)182K(46.65M)52.16M(30.95M)
Free Cash Flow(7.98M)(12.47M)(37.99M)(72.71M)(95.23M)

Perspective Therapeutics, Inc.

AMEX:CATX

Intrinsic Alpha fair value

Locked

Current Price

$0.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.